Emerald Advisers’s Corvus Pharmaceuticals CRVS Stock Holding History

Emerald Advisers’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.83M	Sell	680,016 -5,667	-0.8%	-$78.9K	0.22%	111
2026 Q2	$10.2M	Sell	685,683 -533	-0.1%	-$7.4K	0.24%	108
2026 Q1	$10M	Buy	+686,216	New	+$11M	0.32%	100

Other funds holding CRVS

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Emerald Advisers's CRVS Position: Q3 2026 in Review

Emerald Advisers reduced its Corvus Pharmaceuticals (CRVS) stake by 0.83% in Q3 2026, selling an estimated $78.9K and leaving 680,016 shares worth $7.83M. The position accounts for 0.22% of the portfolio, ranked #111.

Emerald Advisers first reported a position in CRVS in Q1 2026 and has held it in 3 quarters since. The position peaked at $10.2M in Q2 2026. 75 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

Emerald Advisers held 680,016 shares of Corvus Pharmaceuticals worth $7.83M as of Q3 2026.
Emerald Advisers sold 5,667 Corvus Pharmaceuticals shares in Q3 2026, an estimated $78.9K.
Corvus Pharmaceuticals made up 0.22% of Emerald Advisers's portfolio in Q3 2026, its #111 holding.
Emerald Advisers first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
Emerald Advisers's Corvus Pharmaceuticals position peaked at $10.2M in Q2 2026.
75 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on Emerald Advisers's 13F filing for Q3 2026, filed 9 Nov 2026.